PE20001287A1 - PHARMACEUTICAL COMPOSITION CONTAINING DNA FRAGMENTS ENCODING AN ANTIGENIC PROTEIN WITH ANTITUMORAL EFFECT - Google Patents
PHARMACEUTICAL COMPOSITION CONTAINING DNA FRAGMENTS ENCODING AN ANTIGENIC PROTEIN WITH ANTITUMORAL EFFECTInfo
- Publication number
- PE20001287A1 PE20001287A1 PE1999001068A PE00106899A PE20001287A1 PE 20001287 A1 PE20001287 A1 PE 20001287A1 PE 1999001068 A PE1999001068 A PE 1999001068A PE 00106899 A PE00106899 A PE 00106899A PE 20001287 A1 PE20001287 A1 PE 20001287A1
- Authority
- PE
- Peru
- Prior art keywords
- dna
- sequence
- muc
- nucleotides
- pharmaceutical composition
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 4
- 230000000259 anti-tumor effect Effects 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 230000000890 antigenic effect Effects 0.000 title 1
- 108020004414 DNA Proteins 0.000 abstract 5
- 239000002773 nucleotide Substances 0.000 abstract 3
- 102000004127 Cytokines Human genes 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 102000044159 Ubiquitin Human genes 0.000 abstract 1
- 108090000848 Ubiquitin Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE ADN QUE CODIFICA FRAGMENTOS DE UNA PROTEINA; COMO MUCINA (MUC-1); SOBREEXPRESADA EN CELULAS TUMORALES CON EL FIN DE INDUCIR UNA RESPUESTA INMUNOLOGICA ANTITUMORAL ANTIGENO ESPECIFICA EN COMBINACION CON EXCIPIENTES Y ADYUVANTES; DE PREFERENCIA CONTIENEN 2, 3, 4 MOLECULAS DE ADN, ADN PLASMIDICO, CADA UNA DE LAS CUALES CONTIENE UNA SECUENCIA DE ADN DE 200 A 700 NUCLEOTIDOS; QUE CODIFICA UN FRAGMENTO DE MUCINA (MUC-1); SIENDO LAS SECUENCIAS DE ADN DE 200 A 700 NUCLEOTIDOS, SIENDO CADA SECUENCIA CONTIGUA Y PARCIALMENTE SUPERPUESTA EN 50 A 150 NUCLEOTIDOS EN EL EXTREMO 3` Y/O 5' CON RESPECTO A LA SECUENCIA ADYACENTE; TAMBIEN SE REFIERE A UN ADN PLASMIDICO QUE DERIVA DE LA FUSION DEL VECTOR DE EXPRESION pMRS30 CON LAS SECUENCIAS QUE CODIFICA UN FRAGMENTO DE LA PROTEINA MUC-1 DE 181, 496, 631, 271 DE BASES, LAS QUE ESTAN PRECEDIDAS EN EL EXTREMO 5' POR LA SECUENCIA DE 361 BASES CODIFICADORA DE UBIQUITINA Y UNA PORCION LACL DE ESCHERICHIA COLI, LA COMPOSICION CONTIENE ADEMAS UNA CITOQUINA O UN PLASMIDO CODIFICADOR DE CITOQUINA Y PUEDE SER UTIL COMO VACUNAS DE ADN ANTITUMORALREFERS TO A PHARMACEUTICAL COMPOSITION CONTAINING DNA THAT CODES FRAGMENTS OF A PROTEIN; AS MUCIN (MUC-1); OVER EXPRESSED IN TUMOR CELLS IN ORDER TO INDUCE A SPECIFIC ANTI-TUMORAL IMMUNOLOGICAL RESPONSE IN COMBINATION WITH EXCIPIENTS AND ADJUVANTS; PREFERREDLY CONTAINS 2, 3, 4 DNA MOLECULES, PLASMIDIC DNA, EACH OF WHICH CONTAINS A DNA SEQUENCE OF 200 TO 700 NUCLEOTIDES; WHICH CODES A FRAGMENT OF MUCINE (MUC-1); BEING THE DNA SEQUENCES FROM 200 TO 700 NUCLEOTIDES, EACH SEQUENCE BEING CONTIGUOUS AND PARTIALLY SUPERPOSED BY 50 TO 150 NUCLEOTIDES AT THE 3` AND / OR 5 'END WITH RESPECT TO THE ADJACENT SEQUENCE; IT ALSO REFERS TO A PLASMIDIC DNA THAT IS DERIVED FROM THE FUSION OF THE EXPRESSION VECTOR pMRS30 WITH THE SEQUENCES THAT CODE A FRAGMENT OF THE MUC-1 PROTEIN OF 181, 496, 631, 271 OF BASES, WHICH ARE PRECEDED IN THE END 5 ' BY THE SEQUENCE OF 361 UBIQUITIN ENCODING BASES AND A LACL PORTION OF ESCHERICHIA COLI, THE COMPOSITION ALSO CONTAINS A CYTOKINE OR CYTOKINE ENCODING PLASMID AND MAY BE USEFUL AS ANTI-TUMOR DNA VACCINES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1998MI002330A IT1303683B1 (en) | 1998-10-30 | 1998-10-30 | PHARMACEUTICAL COMPOSITION WITH ANTI-TUMORAL ACTION CONTAINING DNACODIFIER FOR FRAGMENTS OF AN ANTIGENIC PROTEIN. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20001287A1 true PE20001287A1 (en) | 2000-12-07 |
Family
ID=11380969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999001068A PE20001287A1 (en) | 1998-10-30 | 1999-10-22 | PHARMACEUTICAL COMPOSITION CONTAINING DNA FRAGMENTS ENCODING AN ANTIGENIC PROTEIN WITH ANTITUMORAL EFFECT |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1124956A2 (en) |
| JP (1) | JP2002528519A (en) |
| CN (1) | CN1324406A (en) |
| AR (1) | AR020927A1 (en) |
| AU (1) | AU1152200A (en) |
| BG (1) | BG105458A (en) |
| BR (1) | BR9914892A (en) |
| CA (1) | CA2348745A1 (en) |
| CO (1) | CO5231134A1 (en) |
| CZ (1) | CZ20011521A3 (en) |
| EA (1) | EA200100395A1 (en) |
| HU (1) | HUP0103784A2 (en) |
| IT (1) | IT1303683B1 (en) |
| MX (1) | MXPA01004186A (en) |
| PE (1) | PE20001287A1 (en) |
| PL (1) | PL348156A1 (en) |
| SK (1) | SK5712001A3 (en) |
| TR (1) | TR200101141T2 (en) |
| WO (1) | WO2000025827A2 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548643B1 (en) | 1994-11-16 | 2003-04-15 | Austin Research Institute | Antigen carbohydrate compounds and their use in immunotherapy |
| EP1257565A4 (en) * | 2000-02-01 | 2005-04-06 | Austin Research Inst | Mucin-1 derived antigens and their use in immunotherapy |
| CN1455680A (en) * | 2000-09-11 | 2003-11-12 | 达纳-法伯癌症协会有限公司 | MUCl extracellular domain and cancer treatment compositions and methods derived therefrom |
| EP1958642A1 (en) | 2000-12-22 | 2008-08-20 | Dana-Farber Cancer Institute | Regulation of cell growth by MUC1 |
| KR101199789B1 (en) * | 2003-03-24 | 2012-11-09 | 더 스크립스 리서치 인스티튜트 | DNA vaccines against tumor growth |
| US7696306B2 (en) | 2003-07-11 | 2010-04-13 | Board of Agents of the University of Nebraska | Compositions and methods for preventing or treating cancer |
| WO2005042573A1 (en) * | 2003-10-24 | 2005-05-12 | Dana-Farber Cancer Institute, Inc. | Modulation of the interaction of muc1 with muc1 ligands |
| US7871784B2 (en) | 2007-02-02 | 2011-01-18 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins |
| WO2008097840A2 (en) | 2007-02-02 | 2008-08-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of muc1 by hsf1 and stat3 |
| CN106279435B (en) * | 2016-08-16 | 2019-06-07 | 新乡医学院 | Target anti-tumor vaccine, encoding gene, expression vector, expression engineering bacteria and the application of VEGF and mucin1 |
| CN113321724B (en) * | 2021-03-24 | 2022-02-01 | 深圳市新靶向生物科技有限公司 | Antigenic peptide related to esophageal cancer driver gene mutation and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1262545B (en) * | 1993-10-25 | 1996-07-02 | Menarini Ricerche Sud S P A A | EXPRESSION SYSTEM FOR EUKARYOTIC CELL LINES |
| WO1998037095A2 (en) * | 1997-02-24 | 1998-08-27 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
-
1998
- 1998-10-30 IT IT1998MI002330A patent/IT1303683B1/en active
-
1999
- 1999-10-18 CZ CZ20011521A patent/CZ20011521A3/en unknown
- 1999-10-18 BR BR9914892-7A patent/BR9914892A/en not_active IP Right Cessation
- 1999-10-18 CN CN99812745A patent/CN1324406A/en active Pending
- 1999-10-18 HU HU0103784A patent/HUP0103784A2/en unknown
- 1999-10-18 SK SK571-2001A patent/SK5712001A3/en unknown
- 1999-10-18 CA CA002348745A patent/CA2348745A1/en not_active Abandoned
- 1999-10-18 JP JP2000579265A patent/JP2002528519A/en active Pending
- 1999-10-18 WO PCT/EP1999/007874 patent/WO2000025827A2/en not_active Ceased
- 1999-10-18 EA EA200100395A patent/EA200100395A1/en unknown
- 1999-10-18 TR TR2001/01141T patent/TR200101141T2/en unknown
- 1999-10-18 AU AU11522/00A patent/AU1152200A/en not_active Abandoned
- 1999-10-18 MX MXPA01004186A patent/MXPA01004186A/en unknown
- 1999-10-18 EP EP99971329A patent/EP1124956A2/en not_active Withdrawn
- 1999-10-18 PL PL99348156A patent/PL348156A1/en unknown
- 1999-10-21 AR ARP990105316A patent/AR020927A1/en unknown
- 1999-10-22 PE PE1999001068A patent/PE20001287A1/en not_active Application Discontinuation
- 1999-10-29 CO CO99068636A patent/CO5231134A1/en not_active Application Discontinuation
-
2001
- 2001-04-20 BG BG105458A patent/BG105458A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL348156A1 (en) | 2002-05-06 |
| WO2000025827A2 (en) | 2000-05-11 |
| ITMI982330A0 (en) | 1998-10-30 |
| WO2000025827A3 (en) | 2000-08-10 |
| EP1124956A2 (en) | 2001-08-22 |
| BG105458A (en) | 2002-06-28 |
| CA2348745A1 (en) | 2000-05-11 |
| IT1303683B1 (en) | 2001-02-23 |
| CZ20011521A3 (en) | 2001-10-17 |
| JP2002528519A (en) | 2002-09-03 |
| TR200101141T2 (en) | 2001-09-21 |
| ITMI982330A1 (en) | 2000-04-30 |
| CN1324406A (en) | 2001-11-28 |
| MXPA01004186A (en) | 2002-06-04 |
| BR9914892A (en) | 2001-07-17 |
| HUP0103784A2 (en) | 2002-02-28 |
| AU1152200A (en) | 2000-05-22 |
| EA200100395A1 (en) | 2001-10-22 |
| AR020927A1 (en) | 2002-06-05 |
| SK5712001A3 (en) | 2002-04-04 |
| CO5231134A1 (en) | 2002-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR008727A1 (en) | COMPOSITIONS AND MELTING PROTEINS INCLUDING A POLYPEPTIDE INCLUDING AN IMMUNOGENIC PORTION OF A PROSTATE PROTEIN OR ITS VARIANT, AND USES THEREOF TO PREPARE A MEDICINAL PRODUCT | |
| AR020601A1 (en) | PEPTIDES OR PROTEINS OF TELOMERASE FOR THE TREATMENT OR PROFILAXIS OF CANCER, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH PEPTIDES OR PROTEINS, USE OF SUCH COMPOSITION FOR THE MANUFACTURE OF MEDICINES AND THE METHOD FOR GENERATING TROUBLESHOOTING | |
| CY1107702T1 (en) | Polypeptides, Streptococcal Group B nucleic acids, and therapeutic compositions and vaccines thereof | |
| PE20001287A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING DNA FRAGMENTS ENCODING AN ANTIGENIC PROTEIN WITH ANTITUMORAL EFFECT | |
| BR0007840A (en) | Her-2 / neu fusion proteins | |
| ES2140418T3 (en) | CHEMICAL FLAVIVIRUS AND / OR RESTRICTED GROWTH FLAVIVIRUS. | |
| AR014514A1 (en) | AN ISOLATED POLINUCLEOTIDE; AN ISOLATED POLYPEPTIDE CODED BY SUCH POLINUCLEOTIDE; AN EXPRESSION VECTOR THAT INCLUDES SUCH POLINUCLEOTIDE; A TRANSFORMED UNCELL WITH SUCH EXPRESSION VECTOR; A PHARMACEUTICAL COMPOSITION AND A VACCINE THAT UNDERSTAND THE POLYPEPTIDE FOR THE TREATMENT OF CANCE | |
| EP1363660A4 (en) | "SUPERIOR MOLECULAR VACCINE BASED ON SELF-REPLICATING RNA, SUICIDE DNA OR NAKED DNA VECTOR, FOR CONNECTING ANTIGEN WITH POLYPEPTIDE TO PROMOTE ANTIGEN PRESENTATION" | |
| DK1349944T3 (en) | Latency-associated peptide of TGF-beta to confer latency to pharmaceutically active proteins | |
| DK0640133T3 (en) | Recombinant DNA molecules encoding aminopeptidase enzymes and their use in the preparation of helminth vaccines | |
| NZ500540A (en) | Purified proteins, fusion proteins, recombinant vector, vaccine, kit, comprising proteins from Actinobacillus pleuropneumoniae | |
| ATE287957T1 (en) | PEPTIDES DERIVED FROM THE BINDING (G) PROTEIN OF THE RESPIRATORY SYNZYTIAL VIRUS | |
| ES2146214T3 (en) | VACCINES FOR ACTINOBACILLUS PLEUROPNEUMONIAE. | |
| ES2069742T3 (en) | PROTEIN OF FELINE CALICIVIRUS CAPSID AND NUCLEOTIDE SEQUENCE. | |
| EP1536006A4 (en) | CANCER ANTIGENS AND THEIR USE | |
| AR036793A1 (en) | NUCLEIC ACID VACCINES USING NUCLEIC ACIDS THAT CODIFY A TUMOR ANTIGEN WITH A NUCLEIC ACID CODIFYING A CYTOKIN AS AN ADJUTIVE | |
| CY1105555T1 (en) | HUMAN POLYPEPTIDES PELLINO | |
| CY1106433T1 (en) | COCCUDIO VACCINE | |
| AR027484A1 (en) | USEFUL FUSION PROTEIN IN THE TREATMENT OR PREVENTION OF ZOSTER HERPES AND IN THE PREVENTION OR TREATMENT OF VARICEL, DNA AND RNA INFECTIONS QUECODIFY SUCH PROTEIN; EXPRESSION VECTORS AND RECOMBINANT MICROORGANISMS THAT INCLUDE SUCH DNA OR RNA; VACCINE COMPOSITIONS THAT INCLUDE DICH | |
| BR9815496A (en) | Nucleic acid vaccines that code for respiratory syncytial virus protein | |
| WO2003093298A3 (en) | Immunogenic peptides | |
| PE20000759A1 (en) | CYTOCHROME HYDROQUINONE OXIDASE GENE OF TYPE BD | |
| ES2138574T1 (en) | IMMUNOGENIC COMPOSITION OF TLP. | |
| BR9713540A (en) | Procedure for the expression of the dengue virus gene | |
| AR015393A1 (en) | ISOLATED POLINUCLEOTIDE MOLECULA, OLIGONUCLEOTIDE MOLECULAR THAT HYBRIDES, RECOMBINATING EXPRESSION VECTOR, TRANSFORMED HOSPED CELL, ISOLATED POLYPEPTIDE, PROCEDURE TO PREPARE IT, ANALOGS OR COMBINED VACCINATION, WINNING PROCESS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |